| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.25 | 2e-05 |
| mRNA | MPS-1-IN-1 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | SNX-2112 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.001 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.002 |
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.007 |
| mRNA | ATRA | FIMM | pan-cancer | AAC | 0.39 | 0.008 |
| mRNA | CCT018159 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.009 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.079 | 0.01 |